Chimeric Antigen Receptor (CAR) Approaches to AD/ADRD (R61/R33 Clinical Trial Not Allowed)

Archived

National Institutes of Health

Description

This Notice of Funding Opportunity (NOFO) aims toprovide a proof-of-principle for a novel strategy for Alzheimer Disease and Alzheimer Related Dementias (AD/ADRD) immunotherapies. Specifically, the goal is to examine if a novel immunotherapeutic approach in cancer immunotherapy with Chimeric Antigen Receptor (CAR) immune cellscould be customized as treatments for AD/ADRD. This NOFO utilizes the R61/R33Exploratory/Developmental Phased Award activity code. The R61 phase provides up to 2 years of support for initial developmental activities. The R33 phase provides up to 3 years of support for expanded activities.

Who can apply

  • State governments
  • County governments
  • City or township governments
  • Special district governments
  • Independent school districts
  • Public and State controlled institutions of higher education
  • Native American tribal governments (Federally recognized)
  • Public housing authorities / Indian housing authorities
  • Native American tribal organizations (other than Federally recognized)
  • Nonprofits with 501(c)(3) status (other than higher education)
  • Nonprofits without 501(c)(3) status (other than higher education)
  • Private institutions of higher education
  • For-profit organizations other than small businesses
  • Small businesses
  • Others

Contact

NIH Grants Information<br/>grantsinfo@nih.gov
grantsinfo@nih.gov

Key dates & funding
  • PostedAug 23, 2023
  • ClosesFeb 7, 2024
  • CFDA93.866
Categories

Pro insight

Edit and export this grant’s proposal template, plus deadline reminders, similar-grant suggestions, and funder history — all available with Pro.

Unlock with Pro